Beam Therapeutics (BEAM) Revenue (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Revenue data on file, last reported at $31.7 million in Q1 2026.

• Quarterly Revenue rose 324.87% year-over-year to $31.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.0 million (up 157.97% YoY) and the FY2025 annual result came in at $139.7 million, up 120.01% from the prior year.
• Revenue declined to $31.7 million in Q1 2026 per BEAM's latest filing, from $114.1 million in the prior quarter.
• Across five years, Revenue topped out at $316.2 million in Q4 2023 and bottomed at $7.4 million in Q1 2024.
• The 5-year median for Revenue is $16.7 million (2022), against an average of $39.6 million.
• The widest annual swing landed in 2022, when Revenue jumped 277433.33%; it then plunged 90.49% in 2024.
• Tracing BEAM's Revenue over 5 years: stood at $20.0 million in 2022, then surged by 1478.04% to $316.2 million in 2023, then sank by 90.49% to $30.1 million in 2024, then soared by 279.52% to $114.1 million in 2025, then sank by 72.19% to $31.7 million in 2026.
• Per Business Quant, the three latest BEAM Revenue figures stand at $31.7 million (Q1 2026), $114.1 million (Q4 2025), and $9.7 million (Q3 2025).

Peer Comparison